Paradigm Shift in Metastatic Malignant Melanoma

Alper SEVINC
Gaziantep University, Faculty of Medicine, Department of Medical Oncology, Gaziantep, TURKEY

ABSTRACT
Substantial advancements have been made in the treatment of metastatic malignant melanoma, for which therapeutic options were quite limited until recently, with the elucidation of molecular pathways that play role in the development and progression of the disease. Although remarkable improvement has been achieved in survival rates with these advancements, a satisfactory response rate could not be obtained or high response rates could not be maintained. In this paper, therapeutic options for metastatic melanoma, particularly ipilimumab and vemurafenib that are also in use in our country, were summarized.

Keywords: Metastatic melanoma, Ipilimumab, Vemurafenib, Paradigm

ÖZET
Metastatik Malign Melanomda Paradigma Değişimi

Anahtar Kelimeler: Metastatik melanom, Ipilimumab, Vemurafenib, Paradigma
1. INTRODUCTION

Melanoma is an important healthcare problem that has become one of the most common cancer types with a dramatic increase in incidence over the last decades.1 Although the skin is the most common site of origin, noncutaneous melanocytes such as those lining the choroidal layer of the eye, mucosal surfaces of the respiratory, gastrointestinal, and genitourinary tracts, and the meninges may also undergo malignant transformation.2

Metastatic melanoma is the most aggressive form of skin cancer with approximately 13,000 deaths per year and a median overall survival (OS) ranging between 8 and 18 months.3 Until recently, therapeutic options for metastatic melanoma were limited; the only approved therapeutic options were dacarbazine, an alkylating agent with a very limited response rate and a median OS of 8 months, and interleukin 2 (IL2), an immunomodulatory agent with an even lower response rate and severe toxicity. With these agents, remissions are infrequent and usually of short duration. Moreover, the treatment is primarily palliative as their effect on survival is not clear.1,4-5

In 2011, there has been a paradigm shift in the treatment of metastatic melanoma with the introduction of ipilimumab (Yervoy™, Bristol-Myers Squibb, Princeton, NJ) and vemurafenib (Zelboraf, Plexxikon/Roche, Auckland, NZ). These agents have both been shown to prolong survival in advanced stage melanoma patients as compared to standard treatments. The clinical benefits of these agents in melanoma have been realized after years of research in the molecular pathogenesis of the disease. With a history of multiple negative phase III studies, melanoma is now a tumor type for the clinical evaluation of paradigm-shifting therapeutic strategies.

2. RECENT ADVANCES

2.1. Immunotherapy

2.1.1. Ipilimumab

Melanoma has long been recognized as an immunogenic tumor due to the presence of infiltrating lymphocytes in resected melanoma, occasional spontaneous regressions, and clinical responses to immune stimulation.3 Advancements in the understanding of immune cellular signaling pathway abnormalities that promote the development and progression of melanoma has led investigators to search for novel strategies to overcome immune evasion.3 Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is a immunomodulatory molecule expressed on activated T-cells and T-regulatory cells.6 This molecule delivers a negative costimulatory signal that downregulates T-cell activity. Ipilimumab is a fully human IgG1 monoclonal antibody that blocks this molecule, and thus enhances T-cell activity and recognition of the tumor by T-cells not only in malignant melanoma but also in several cancer types. Ipilimumab is now the first treatment in a randomized study to demonstrate a clear OS benefit in metastatic melanoma.6

In a randomized, double-blind phase II study, previously treated, advanced stage melanoma patients were randomized to receive a fixed dose of ipilimumab of either of 0.3 mg/kg, 3 mg/kg, and 10 mg/kg every 3 weeks for four cycles followed by maintenance therapy every 3 months. It was observed that the best overall response rate was increased in a dose-dependent fashion, and ipilimumab showed clinical activity at doses of 3 mg/kg and higher.7 In another phase II study, chemotherapy-naïve metastatic melanoma patients were randomized to receive ipilimumab at 3 mg/kg every 4 weeks for four cycles either alone or in combination with dacarbazine 250 mg/m2/day for 5 days for up to six courses. The objective response rates were 5.4% and 14.3% in the monotherapy and combination therapy arms, respectively, and there was no significant difference between the two arms in this respect.6 Further studies of ipilimumab at a dose of 10 mg/kg showed best overall response rates ranging between 5.8% and 15.8%.8

In a phase III study, patients with unresectable, advanced stage melanoma that had progressed while the patients were receiving therapy were randomized to receive ipilimumab plus glycoprotein 100 (gp100) peptide vaccine, ipilimumab alone, or gp100 alone. All treatments were administered every 3 weeks for four cycles. The primary efficacy endpoint of the study was OS, which was shown to be prolonged in ipilimumab monotherapy and combination arms as compared to gp100 monotherapy arm (10 months and 10.1 months vs. 6.4 months,
respectively). Moreover, there was no additional benefit of the vaccine as there was no significant difference between the two ipilimumab arms with respect to OS.8 On the basis of these results, ipilimumab received United States Food and Drug Administration (FDA) approval for the treatment of metastatic melanoma in 2011.6 Following the approval of ipilimumab by the FDA, the drug was integrated into the National Comprehensive Cancer Network (NCCN) melanoma guidelines. More recently, a footnote regarding re-induction with ipilimumab was added to the section in the guidelines on metastatic disease. Re-induction with ipilimumab was emphasized in patients not experiencing a significant toxicity during previous therapy and relapse after clinical response or progress after stable disease > 3 months. In the above-mentioned phase III study randomizing previously treated patients with metastatic melanoma to receive ipilimumab plus gp100, ipilimumab alone, or gp100 alone, the disease control rate was found 52%-67% among those receiving re-induction with ipilimumab, and the safety profile during re-induction was consistent with that of overall study.9

Another phase III study randomized previously untreated metastatic melanoma patients to receive dacarbazine in combination with ipilimumab or placebo. It was observed that OS was significantly longer in patients receiving ipilimumab plus dacarbazine as compared to those receiving placebo plus dacarbazine (11.2 months vs. 9.1 months). The survival benefit was also observed when the patients were grouped according to age, sex, Eastern Cooperative Oncology Group (ECOG) performance status, baseline serum lactate dehydrogenase level, and substage of the disease.10 However, response rates were not satisfactory in both phase III studies (Table 1).3 The low clinical response rate with ipilimumab treatment has been suggested to be increased by either through improved patient selection, through combination with other therapies or by applying higher doses.3 In an attempt to increase response rates and improve clinical outcomes, two drugs may be used sequentially; a BRAF inhibitor to reduce the tumor load and then use ipilimumab to maintain the response.11 The efficacy of this approach was tested in a retrospective analysis of patients receiving vemurafenib or dabrafenib and ipilimumab as part of a trial or expanded access program. In this analysis, 12 out of 28 patients receiving a BRAF inhibitor first were unable to complete treatment with ipilimumab due to rapid disease progression. A logistic regression showed elevated LDH, an ECOG performance status of 1 and the presence of brain metastases to be the most significant risk factors for rapid progression. It was suggested that patients having two or more of these risk factors could potentially benefit from ipilimumab as the first part of the sequential treatment regimen. Of note, there was no correlation between the number of risk factors at baseline and rate of disease progression in patients who received ipilimumab first and were subsequently treated with a

| Table 1. Comparison of CTLA-4 blocker, ipilimumab and BRAF inhibitor, vemurafenib in phase III studies |
|---------------------------------|---------------------------------|
| Ipilimumab                      | Vemurafenib                     |
| Indication                     | Any melanoma                   | Unresectable or metastatic melanoma harboring a BRAF V600E mutation |
| Mechanism of action             | Blockade of CTLA-4              | Inhibition of mutant BRAF V600E |
| Route of administration        | Intravenous                     | Oral |
| Contraindication               | Autoimmune diseases            | Wild-type BRAF |
| Best overall response rate      | 15.2%                           | 48% |
| PFS                            | 2.86 months                     | 5.3 months |
| Durable response               | Yes                             | No |
| Adverse events                 | Immune-mediated AEs most commonly affecting the skin and gastrointestinal tract | Cutaneous events including SCC, arthralgia and fatigue |
BRAF inhibitor upon disease progression. Furthermore, my colleagues and I reported a case of malignant melanoma with multiple brain metastases that survived for 40 months with the sequential use of ipilimumab and vemurafenib. Currently, there is no reliable predictor of benefit for ipilimumab. One group reported that the presence of a BRAF mutation does not predict clinical benefit of ipilimumab. On the other hand, it has been shown that ipilimumab increases the frequency of T-cells with inducible co-stimulatory molecule (ICOS) and that ICOS T-cells are necessary for response to ipilimumab. In order to draw a definite conclusion about this issue, it has to be determined whether or not baseline ICOS T-cells predict benefit of ipilimumab. And, there is evidence suggesting that a higher response rate can be achieved when ipilimumab is administered at a higher dose (10 mg/kg) than the dose approved by the FDA. In addition to better patient selection, ipilimumab has been combined with other modalities to increase response rates. Although the phase III study of ipilimumab plus dacarbazine failed to show an improved disease control rate and overall response rate with ipilimumab therapy, this question was not addressed in that particular study. In the randomized phase II study of ipilimumab with or without dacarbazine, patients receiving ipilimumab plus dacarbazine had higher disease control and best overall response rates, although the difference between the two treatment arms did not reach statistical significance. In a phase I study of ipilimumab and temozolomide, an overall disease control rate of 67% was achieved, which is much higher than seen in single agent studies. In a phase I study of ipilimumab and bevacizumab, response was achieved in 8 out of 21 patients with unresectable, advanced-stage melanoma; however, immune-related toxicity also seemed to be enhanced with this combination.

2.2.2. Anti-PD-1
Programmed death-1 (PD-1), as CLTA-4, is a costimulatory molecule for T-cell activation and has become a target for cancer immunotherapy on the basis of experimental studies suggesting that the blockage of the interaction between PD-1 and its ligand PD-L1 potentiates immune response and mediates antitumor immunity. Indeed, early phase studies have shown that agents targeting the interaction between these two molecules exert antitumor activity and induce durable tumor response in advanced cancers, including melanoma.

2.2. Targeted Treatment
2.2.1. BRAF Inhibitors
2.2.1.1. Vemurafenib
In 2002, it was discovered that cutaneous melanoma is a molecularly heterogeneous disease harboring an activating mutation in the gene encoding for the serine-threonine protein kinase B-raf (BRAF) in two thirds of patients. The vast majority of the activating BRAF mutations involve a valine for glutamate substitution at codon 600 (V600E), which results in constitutive activation of the mitogen-activated protein kinase pathway (MAPK), leading to oncogenic cell proliferation. Recently, highly selective BRAF inhibitors that are capable of silencing BRAF V600E mutations with little effect on wild-type BRAF have been developed. Vemurafenib (PLX-4032, RG7204) is a specific inhibitor of mutant BRAF kinase, and is the second agent, after ipilimumab, that has been shown to improve OS in patients with advanced stage melanoma.

In a phase I study, vemurafenib induced partial or complete response in 81% of patients with metastatic melanoma harboring a BRAF V600E mutation. In a pivotal phase II study of vemurafenib, overall response was achieved in 52.3% of previously treated patients with BRAF V600E mutation-positive metastatic melanoma. These results were collaborated with a more recent phase II study, in which vemurafenib induced clinical response in 53% of patients with previously treated BRAF V600E mutation-positive metastatic melanoma. A phase III randomized study comparing vemurafenib and dacarbazine showed that vemurafenib treatment significantly prolonged 6-month OS as compared to dacarbazine (84% vs. 64%). The interim analysis for OS and final analysis for progression-free survival (PFS) demonstrated a relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression with vemurafenib when compared to dacarbazine. The most common adverse events observed during treatment with ve-
murafenib were cutaneous events, arthralgia and fatigue (Table 1). Cutaneous squamous-cell carcinoma (SSC), keratoacanthoma, or both developed in 18% of patients which were treated through simple excision. This phase III study was the first-in-melanoma showing an inhibition of an aberrantly overactive signaling pathway improving survival. Based on these results, the FDA approved vemurafenib in 2011.1

2.2.1.2. Dabrafenib

There are several other BRAF inhibitors that are currently undergoing clinical testing. Another BRAF inhibitor, dabrafenib (GSK2118436), also showed clinical activity with minimal toxicity in a phase I/II study. In a phase III study of patients with previously untreated BRAF V600E mutation-positive melanoma, dabrafenib showed a significant improvement in progression-free survival as compared to dacarbazine (5.1 months vs. 2.7 months). Among patients receiving dabrafenib, 50% achieved an objective response confirmed by an independent review committee. Besides their efficacy in BRAF V600E mutations, vemurafenib and dabrafenib have both shown activity in V600K mutant melanomas, which is the most common non-V600E mutation in melanoma patients. However, these agents are not currently approved for this indication.3

In brief, both agents have shown clinical activity with high response and minimal toxicity in patients with BRAF V600E mutations; however, both therapies have a relatively short duration.3 The most important AEs related to the use of BRAF inhibitors are cutaneous events, such SCCs and keratoacanthomas develop as a result of the paradoxical transactivation of MAPK by these agents.3

2.2.2. Other Targeted Agents

In addition to BRAF, molecular alterations involving oncogenes including NRAS, MEK, ERK, KIT, CDK4, CCND1, ERBB4, AKT, NEDD9, GNAQ and GNA1, transcription factors including MITF, MYC and ETV1, and tumor suppressors including CDKN2A, TP53, BAP1 and PTEN have been identified in melanoma patients. Among those, MEK is an attractive target as it is downstream of both activated BRAF and NRAS.1 It was shown in preclinical studies that the sensitivity to MEK inhibition was higher in melanoma cells harboring a BRAF mutation than those harboring activating NRAS mutations and wild-type BRAF genes. While small-molecule MEK inhibitors completely abrogated tumor growth in BRAF mutant xenografts, they showed a partial inhibitory effect on RAS mutant tumors.1 MEK inhibitors under clinical development include CI-1040, PD-0325901, trametinib (GSK1120212), and AZD6244. Early-phase studies have shown clinical activity of trametinib,24 and trametinib improved PFS and OS in patients with BRAF-mutant melanoma as compared to chemotherapeutic agents, dacarbazine and paclitaxel, in a phase III study.25 On the other hand, some pharmacological and toxicity issues limit the activity of CI-1040 and PD-0325901.

Another molecular pathway involved in the pathogenesis of melanoma is c-KIT signaling pathway which plays a key role in the differentiation, proliferation, and migration of normal melanocytes. However, this tyrosine kinase receptor also contributes to the pathogenesis of a subset of melanomas that do not harbor NRAS or BRAF mutations. c-KIT mutations have been identified in a substantial proportion of melanomas originating from mucosa, acral and chronic sun-induced damaged skin.26,27

2.3. Combined Targeted Therapies

To overcome low response rates with ipilimumab therapy and short durations of response in targeted therapies, novel combinations of immune targeted therapies are being tested. It has been suggested that combining immunotherapy with a BRAF-targeted therapy may allow achieving high response rates and durable response rates. Based on preclinical studies suggesting a strong rationale for combining a BRAF inhibitor with an immune-stimulating agent, a phase I/II study was planned to assess the safety and efficacy of ipilimumab and vemurafenib combination and to show preliminary evidence of anti-tumor efficacy and survival in comparison to historical results following treatment with either agent alone in metastatic melanoma patients with V600 BRAF mutations. Unfortunately, the results from this study will not be available until 2015.
Another promising strategy is the BRAF/MEK inhibitor combination showing greater activity against cancer cells harboring BRAF mutations as compared to either drug alone, and decreased incidence of hyper-proliferative skin lesions related to BRAF inhibitor use.1 In general, these strategies have focused on either inhibiting additional targets within the same pathway or inhibiting a different pathway or cellular process involved in the pathogenesis or drug resistance of melanoma.1 Studies combining CTLA-4 and other immunomodulatory antibodies, and/or vaccines are also underway. These strategies are based on the current understanding of molecular or signaling pathways involving in the pathogenesis of the disease, availability of agents and although limited, preclinical data suggesting an additional benefit of combination therapy without a further increase in normal tissue toxicity.1

2.4. Local Studies in Turkey

To the best of our knowledge, the number of studies conducted on metastatic melanoma patients receiving ipilimumab or vemurafenib in our country is quite limited. In a retrospective analysis of 75 metastatic melanoma patients treated under an expanded access program in Turkey, it was found that none of the patients achieved a complete response with ipilimumab therapy. The disease control rate was found 36.1%, and the time to progression was 2.7 months.29 Another study of ipilimumab retrospectively evaluated demographic and clinical characteristics of 20 malignant melanoma patients and reported a median PFS of 2.7 months and an OS of 8.6 months. Four of 13 patients who were screened for BRAF V600E mutations received vemurafenib after ipilimumab. Comparison of the patients who did or did not receive sequential vemurafenib therapy revealed an improved OS in those receiving sequential vemurafenib (6.3 months vs. 19 months).30 In another retrospective study, clinical and demographic characteristics of 13 stage IV metastatic melanoma patients receiving vemurafenib were evaluated. Of the patients, 6 had multiple brain metastases, and 4 had previous ipilimumab therapy. Despite the presence of poor prognostic factors, 15.3% of the patients achieved complete response while 23.1% achieved partial response. Although the median PFS and OS were 3.45 months and 5.49 months, respectively, among the overall study population, subgroup analyses revealed median PFS of 3.30 months and a median OS of 4.54 months among patients with previous ipilimumab therapy. The comparison of patients with and without brain metastases showed a poorer PFS and OS among those with brain metastases.31

Another study from Turkey was report of a metastatic melanoma case with multiple unresectable brain metastases who survived 40 months with the sequential use of ipilimumab and vemurafenib.12

CONCLUSION

Improvements in our understanding of the molecular and signaling pathways involved in the development and progression of the disease have led to the development of targeted therapies capable of improving survival in advanced stage melanoma patients. Currently, the paradigm-shifting molecules, ipilimumab and vemurafenib are the first-line treatment options for these patients. Sequential usage of these agents may also be the leading way of treating melanoma patients in the near future. However, intrinsic and acquired resistance to these agents will allow investigators to develop novel combination strategies that will hopefully improve clinical benefit in melanoma patients.

REFERENCES


Correspondence: Prof. Dr. Alper SEVINC Gaziantep Üniversitesi Tip Fakültesi Tibbi Onkoloji bölümü Dali GAZIANTEP / TURKEY Tel: (+90.555) 241 46 87 Faks: (+90.342) 472 07 18 e-mail: sevinc@gaziantep.edu.tr